MedTrace Logo

Bioavailability Study of Magne-B6 New Formulation

NCT06386211 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-09-12

No results posted yet for this study

Summary

The purpose of the study is to assess the relative bioavailability of two Magne-B6 preparations, in fasting conditions.

Conditions

  • Healthy Volunteers

Interventions

DRUG

MAGNE-B6 Oral Solution

Oral solution.

DRUG

MAGNE-B6 New Formulation Tablet

New formulation tablet.

Sponsors & Collaborators

  • Opella Healthcare Group SAS, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • CHC Clinical studies · Opella Healthcare Group SAS, a Sanofi Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2024-08-24
Completion
2024-08-24

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06386211 on ClinicalTrials.gov